Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes.

Leukemia & lymphoma·2026
Same author

Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.

Med (New York, N.Y.)·2026
Same author

CanAssist Breast Risk Stratification in Multifocal/Multicentric Breast Cancer: To Test Each Focus or Not?

Archives of pathology & laboratory medicine·2026
Same author

Benzazepines Derivatives: Synthetic Strategy, Structural-Activity Relationships, and Medical Potential as Dopamine and Serotonin Receptor Modulators.

ACS omega·2026
Same author

Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia.

Blood cancer discovery·2026
Same author

Synthesis and Biological Activity of Guanidine Scaffold: A Comprehensive Review.

Anti-inflammatory & anti-allergy agents in medicinal chemistry·2026

Related Experiment Video

Updated: Aug 18, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Targeting inflammation in lower-risk MDS.

Jesus D Gonzalez-Lugo1, Amit Verma1

  • 1Division of Hemato-Oncology, Department of Oncology, Montefiore-Einstein Cancer Center, Blood Cancer Institute, Bronx, NY.

Hematology. American Society of Hematology. Education Program
|December 9, 2022
PubMed
Summary

Myelodysplastic syndromes (MDS) involve ineffective blood cell production due to inflammation. Targeting inflammatory pathways offers a promising therapeutic strategy for low-risk MDS patients.

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K

Related Experiment Videos

Last Updated: Aug 18, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.7K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
  • Characterized by ineffective hematopoiesis, peripheral cytopenias, dysplasia, and risk of acute myeloid leukemia.
  • Most patients present with lower-risk disease, necessitating therapies to improve blood counts.

Purpose of the Study:

  • To explore the role of inflammation in the pathogenesis of low-risk MDS.
  • To identify therapeutic strategies targeting inflammatory pathways in MDS.

Main Methods:

  • Review of existing literature on MDS pathogenesis and inflammatory pathways.
  • Analysis of the impact of specific cytokines (IL-1b, IL-6, IL-8) and spliceosome mutations on hematopoiesis.
  • Examination of therapeutic approaches targeting inflammatory mediators and the TGF-β pathway.

Main Results:

  • Elevated inflammatory cytokines contribute to dysplastic differentiation and aberrant stem cell growth in MDS.
  • Spliceosome mutations activate pro-inflammatory NF-κB pathways.
  • Targeting TGF-β pathway ligands (e.g., luspatercept) has shown therapeutic success.

Conclusions:

  • An inflammatory microenvironment is integral to the pathogenesis of clonal hematopoiesis and low-risk MDS.
  • Anti-inflammatory strategies are under investigation in ongoing clinical trials for MDS.